Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Wegovy maker Novo Nordisk has cut a U.S. sales team focused on obesity and diabetes education for healthcare providers, ...

Novo Nordisk's shares rose by 5.4% on Thursday as investors turned more positive about the Danish drugmaker's prospects ...

Novo Nordisk's Wegovy will soon come in a pill form that's as effective as with a needle. A new study shows Wegovy taken once ...

The Novo Nordisk RTO mandate could be a strategy to encourage attrition, but if community-building is the goal, additional ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

The changes come five weeks into the tenure of new CEO Maziar Mike Doustdar. Doustdar was tapped to replace Novo's previous ...

The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.

Novo Nordisk , looking to turn around slowing growth of its blockbuster weight-loss drug Wegovy, plans to test whether its ...